Thyme (Thymus vulgaris L.): A Comprehensive Reference
1. Identity and Botanical Description
Botanical and Chemical Names
Thyme is scientifically known as Thymus vulgaris L. and belongs to the Lamiaceae family, a diverse group of aromatic herbs that includes mint, basil, and rosemary. The genus Thymus contains over 350 species, with Thymus vulgaris being the most widely cultivated for culinary and medicinal purposes. Other species used medicinally include Thymus zygis (Spanish thyme), which is often used interchangeably with T. vulgaris in herbal medicine. The common name "thyme" derives from the Greek; the name thymus is derived from the Greek word thumos, which means "courage" or "to fumigate," reflecting its historical use in ancient cultures as a symbol of bravery and for purification rituals.
Plant Description and Habitat
It is a bushy, woody-based evergreen subshrub with small, highly aromatic, grey-green leaves and clusters of purple or pink flowers that bloom in early summer. Native to the Mediterranean region, particularly southern Europe, this small perennial herb thrives in sunny, well-drained locations. The plant typically grows to a height of 15–30 cm (6–12 inches) and is renowned for its compact, bushy growth habit that makes it popular in both culinary gardens and ornamental landscapes. Thyme is native to the Mediterranean region of Europe but cultivated in many parts of the world.
Chemotypes
Six different chemotypes have been described for T. vulgaris. The chemotypes are named after their dominant monoterpene: geraniol (G), α-terpineol (A), thuyanol-4 (U), linalool (L), carvacrol (C), and thymol (T). The thymol chemotype is commercially predominant and the most widely studied for medicinal applications.
Common Forms and Preparations
Thyme is grown for commercial purposes in many countries for the production of the dried leaves, thyme oil, thyme extracts, and oleoresins. Medicinal preparations are made by comminuting (reducing into tiny pieces) the leaves and flowers, by expressing the juice of the leaves and flowers, or as dry, liquid, and soft extracts. Other common forms include herbal teas (infusions/decoctions), tinctures, syrups (commonly combined with ivy or primrose for respiratory indications), and essential oils obtained by steam distillation. T. vulgaris leaves are oval to rectangular in form, and the somewhat fleshy aerial components are used for volatile oil production, principally by steam distillation.
2. Historical and Traditional Use
Ancient Civilizations
Ancient Sumerian and Egyptian cultures used thyme to embalm the dead and for its medicinal properties; the Romans flavored cheese and alcoholic beverages with it, and burned it to ward off dangerous animals. In ancient Egypt, thyme was rubbed on a corpse along with other herbs like rosemary before being wrapped as part of the mummification process. The Egyptians also used thyme as a pain reliever, and it was included in many of their medicines.
The ancient Greeks used it in their baths and burned it as incense in their temples, believing it was a source of courage. Hippocrates, who lived around 460 BCE to 370 BCE and is considered "the father of Western medicine," recommended thyme for respiratory diseases and conditions. The Romans thought that eating thyme before or during a meal would cure poisons, making it especially popular among Roman emperors. Thyme was also often given to Roman soldiers upon their leaving for battle, as a sign of courage.
Medieval and Renaissance Periods
The tradition of giving thyme as a farewell gift to soldiers continued throughout the Middle Ages of England, where it also caught on as a popular spice for use in cooking. In the Renaissance and Enlightenment eras, thyme's prominence extended beyond medicinal uses into the realms of science and literature. Apothecaries and physicians during these periods continued to exploit thyme's therapeutic properties, using it to formulate remedies for a variety of ailments. The herb was often recommended for digestive problems, respiratory issues, and as a means to disinfect and heal wounds.
In the 19th century AD, constituents of thyme oils were used by dentists to treat oral abscesses and inflammation and as an antiseptic. Before the advent of modern antibiotics, oil of thyme was used to medicate bandages.
Traditional Indications
In traditional medicine, the plant is used against a range of ailments such as various respiratory-related disorders, gastrointestinal disorders, and hypertension. Regulatory bodies have recognized several of these traditional applications: thyme has been traditionally used in herbal medicine to help relieve coughs (spasmolytic), as well as indigestion/flatulent dyspepsia and colic (carminative), and to help relieve the symptoms of bronchitis and mucus buildup of the (upper) respiratory tract (anti-catarrh), according to the EMA (2014), ESCOP (2003), and Blumenthal et al. (2000).
3. Key Constituents and Active Compounds
Essential Oil Composition
The essential oils found in thyme include thymol, which is a major component responsible for the plant's antiseptic properties, and carvacrol, another primary component with similar functions. Other essential oils present are p-cymene, γ-terpinene, linalool, and 1,8-cineole. Oil of thyme, the essential oil of common thyme, contains 20–54% thymol. The essential oil of thyme is known as a mixture of natural constituents present in relatively different quantities or concentrations. It contains variant chemical compounds including monoterpene hydrocarbons (28.69%), oxygenated monoterpenes (56.53%), oxygenated sesquiterpenes (1.84%), and sesquiterpene hydrocarbons (5.04%).
Phenolic and Non-Volatile Compounds
The main active constituents of T. vulgaris include terpenes; phenols; thymol; carvacrol; terpenoids; glycosides of phenolic monoterpenoids; eugenol and aliphatic alcohols; flavonoids such as thymonin, cirsilineol, and 8-methoxycirsilineol; biphenyl compounds of monoterpenoid origin; caffeic and rosmarinic acids; and saponins. Several authors have identified the presence of phenolic compounds such as quinic, rosmarinic, caffeic, p-coumaric, syringic, geranic, p-hydroxybenzoic, gentisic, and ferulic acids, as well as apigenin, luteolin, cirsimaritin, xanthomicrol, and thymusin. The methanolic extract of T. vulgaris leaves contains active compounds including alkaloids, phenolic compounds, flavonoids, essential oils, tannins, triterpenoids, steroids, and saponins.
Thymol: The Principal Bioactive Molecule
Thymol, chemically identified as 2-isopropyl-5-methylphenol, is a monoterpene phenol. Gas chromatographic analysis reveals that the most abundant volatile component of thyme leaves is thymol, at 8.55 mg/g. For centuries, it has been used in traditional medicine and has been shown to possess various pharmacological properties including antioxidant, free radical scavenging, anti-inflammatory, analgesic, antispasmodic, antibacterial, antifungal, antiseptic, and antitumor activities.
4. Mechanisms of Action
Antimicrobial Mechanisms
The most commonly accepted explanation for the antimicrobial mechanism of thymol is that changes in membrane tension caused by thymol destabilize membrane structure. The antibacterial mechanism shows that thymol's ability to bind to the lipid layer of the cell membrane increases its surface curvature. The hydrophilic part of the molecule interacts with the polar part of the membrane, while the hydrophobic benzene ring and lipid side chains sink into the inner layer of the biofilm. This leads to a dramatic change in membrane structure through the instability of the lipid layer, decreased elasticity, and increased fluidity.
Several studies have shown that thymol can lead to the breakdown of adenosine triphosphate (ATP) synthesis, which disrupts the bioenergy balance and damages mitochondrial energy production. It may also cause metabolic disorders of Na⁺ and Ca²⁺ in cells to produce excessive oxygen free radicals, leading to cell death.
Studies have revealed that thymol predominantly exerts its antifungal activity by disrupting the structure of the cell membrane, affecting membrane ion channels, altering DNA structure, and interfering with the material and energy metabolism of the pathogen. Thymol induces a significant increase in malondialdehyde (MDA) concentration and a remarkable decrease in ergosterol content, showing potential antifungal activity due to cell membrane damage originating from lipid peroxidation and the disturbance of ergosterol biosynthesis.
In complex essential oil studies, 21% synergistic, 42% additive, 36% indifferent, and 1% antagonistic interactions were observed between constituent molecules. Most interactions were between the weak and highly active molecules, and interestingly, no synergistic interaction was observed between the highly active compounds. Synergistic and additive interactions between the strong and weaker antimicrobial constituents present in thyme essential oil enhance its overall antimicrobial efficacy.
Anti-Inflammatory Mechanisms
Inflammation can be modulated by targeting essential molecular pathways such as MAPK, NF-κB, JAK/STAT, and arachidonic acid signaling. Thymol has been shown to influence these pathways, reducing the production of pro-inflammatory cytokines and mediators. More specifically, thymol inhibits the dissociation of the IκB protein and NF-κB dimer and the activation of the mitogen-activated protein kinase (MAPK) signaling pathway to relieve inflammation. Measurements of proinflammatory cytokine mRNA expression and secreted protein levels in LPS-activated macrophages showed that thyme essential oil prepared at the beginning of the flowering period acted as a potent inhibitor of the synthesis of IL-6, IL-8, IL-β, and TNF-α.
Antioxidant Mechanisms
The antioxidant effects of thymol are largely attributed to scavenging of free radicals, enhancing endogenous enzymatic and non-enzymatic antioxidants, and chelation of metal ions. Among extract fractions, the ethyl acetate fraction showed high antioxidant activity in the DPPH (84.1 ± 0.88) and ABTS (87.1 ± 0.89) assays.
Spasmolytic (Bronchodilatory) Mechanisms
Thyme extracts have been found to exhibit spasmolytic activity in the guinea-pig ileum and trachea in a dose-dependent manner. The extracts were found to be non-competitive antagonists to specific agonists (acetylcholine, histamine, noradrenaline) and unspecific agonists (barium chloride).
5. Scientific Evidence by Area of Use
5.1 Respiratory Health: Acute Bronchitis and Cough
This is the area with the strongest clinical evidence for thyme, supported by multiple controlled trials and regulatory recognition across Europe.
Thyme-Primrose Combination (Bronchipret TP / Bronchicum): In a double-blind, randomized, placebo-controlled, multicenter, prospective study, the clinical efficacy and tolerability of a fixed combination of thyme fluid extract and primrose root tincture was investigated at a dosage of 30 drops (1 ml), taken orally five times daily. One hundred fifty outpatients (97 women, 53 men) suffering from acute, not previously treated bronchitis, lasting for less than 48 hours, were randomized and treated with either verum (75 patients) or placebo (75 patients) over a time period of 7–9 days. In the verum group, the Bronchitis Severity Score (BSS) decreased from 12.0 ± 4.4 points at baseline to 1.0 ± 2.1 at study end, compared to a decrease from 11.7 ± 4.3 points to 6.5 ± 4.8 in the placebo group. The inter-group difference of 5.8 points was highly significant (p ≤ 10⁻³) in favour of the verum medication. At the end of the study, significantly more patients were symptom free in the verum group (58.7%) than in the placebo group (5.3%).
Kemmerich 2007 — Thyme-Primrose Dry Extract: The objective of the study was to assess the efficacy and tolerability of a fixed combination of dry extracts of thyme herb and primrose root and matched placebo in patients suffering from acute bronchitis with productive cough. In a double-blind, placebo-controlled, multicenter Phase IV study, 361 outpatients with acute bronchitis and ≥10 coughing fits during the day were randomly assigned to an 11-day treatment (1 tablet three times daily) with either the thyme-primrose combination (N = 183) or placebo (N = 178).
Thyme-Ivy Combination (Bronchipret Drops): The herbal treatment significantly reduced cough compared to placebo (77.6% vs. 55.9%). Adverse effects were low and similar to those in the placebo group (3.8% and 4.5% respectively).
Large-Scale Matched-Pair Comparison: A study compared the herbal medication Bronchipret® with various other pharmacotherapeutic options for acute bronchitis. The study was designed as a matched-pair comparison of 7,783 patients. Clinical outcomes of bronchitis and adverse reactions were documented. The data were evaluated by comparing the treatment success of the test medication and 3 control groups using ordinal regression. The results suggest that the clinical effectiveness of Bronchipret® was not less than with synthetic drugs. There was a tendency for better results with Bronchipret®, particularly in the treatment of adults.
Pediatric Evidence: In an open, multicenter study, 154 children aged 2 months to 14 years (mean 4.4 years) with bronchial catarrh or bronchitis were treated daily with 15–30 ml of thyme syrup, containing 97.6 mg of thyme liquid extract per ml, for a period of 7–14 days (mean 7.9 days). Compared to the start of the treatment, an improvement of coughing was reported in 93.5% of patients. However, this was an open-label study without a control group, limiting its strength as evidence.
Recent Comparative Trial: In a three-arm, open-label, randomized clinical trial, patients with acute bronchitis were assigned to groups receiving Ivy extract EA 575 (Prospan® Cough Drops), Ivy/Thyme extract combination (Bronchipret® Drops), or Thyme/Primrose extract combination (Bronchicum® Drops) according to their respective labels. The primary endpoint was the assessment of non-inferiority. In total, 325 adult patients were considered for evaluation. Non-inferiority of Ivy extract was statistically significant against both comparators (both p < 0.0001). Superiority of Ivy extract was statistically significant against Ivy/Thyme extract (p < 0.0001) but missed statistical significance against Thyme/Primrose extract (p < 0.0607).
Regulatory Status: The EMA's Herbal Medicines Committee (HMPC) classifies thyme preparations under "traditional use," meaning that although there is insufficient evidence from clinical trials, the effectiveness of these herbal medicines is plausible and there is evidence that they have been used safely in this way for at least 30 years (including at least 15 years within the EU).
Evidence Strength: Moderate. Multiple randomized controlled trials support thyme combinations for acute bronchitis and productive cough, though most trials use thyme in combination with other herbs (ivy, primrose) rather than as a single agent, making it difficult to isolate thyme's independent contribution.
5.2 Antimicrobial Activity
T. vulgaris essential oil and its major constituents exhibit potent antibacterial and antifungal activities. Research has shown that the antibacterial activity of essential oil containing thymol showed antibacterial activity against most Gram-positive and Gram-negative bacteria. Evidence has confirmed its wide antibacterial spectrum against Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli, and other foodborne pathogenic bacteria. The majority of this evidence is from in vitro studies; controlled clinical trials evaluating thyme for treating human bacterial infections are lacking.
Evidence Strength: Strong preclinical (in vitro and some animal) evidence; human clinical trial data for antimicrobial use are absent.
5.3 Anti-Inflammatory Activity
In preclinical research, thymol at doses of 7.5, 15, and 30 mg/kg was investigated and dose-dependently and significantly (p < 0.05) decreased paw-licking and edema diameter parameters in formalin (phases I and II) and egg albumin-induced models. Despite promising preclinical results, challenges such as low bioavailability and toxicity at high doses limit their clinical use.
Evidence Strength: Preliminary; primarily animal and in vitro evidence. Human clinical evidence for anti-inflammatory applications is lacking.
5.4 Antioxidant Activity
T. vulgaris has been shown to have different therapeutic effects, including antioxidant activity. Studies using DPPH and ABTS assays have confirmed free radical scavenging in extracts. However, most evidence remains from laboratory assays.
Evidence Strength: Demonstrated in vitro; translation to human clinical benefit has not been established in controlled trials.
5.5 Antifungal Activity
With low MIC values, negligible host toxicity, and desirable ADME properties, thymol has immense potential as a potent antifungal drug that can be used for developing mechanism-based drugs, as it has specific binding affinity for specific target proteins. Thymol has also been shown to be effective against various fungi that commonly infect toenails, though the evidence for this specific clinical indication remains limited in terms of rigorous human trials.
Evidence Strength: Predominantly in vitro and animal studies; clinical trials in human fungal infections are limited.
5.6 Cardiovascular and Blood Pressure
Antihyperlipidemic effects of thymol have been described in pharmacological review literature, via increasing the levels of high-density lipoprotein cholesterol and decreasing the levels of low-density lipoprotein cholesterol in the circulation. A 2023 study of people with high blood pressure found that thyme herbs can reduce systolic and diastolic blood pressure and keep it in a standard range. However, further research on the effects of thyme on high blood pressure is necessary.
Evidence Strength: Preliminary; the blood pressure finding requires replication in larger, well-controlled studies.
5.7 Gastrointestinal Health
Thymol, a natural monoterpene phenol that is mostly found in thyme, exhibits multiple biological functions as a potential adjuvant for inflammatory bowel disease (IBD). Research has described the role of thymol in the modulation of inflammation, oxidative stress, and gut microbiota against gastrointestinal disease. Pathogen infection in the intestinal lumen reduces mucus secretion and expressions of tight junction proteins, increasing intestinal permeability (a "leaky gut"). Thymol has been shown to defend against pathogen invasion, promote mucus secretion, and enhance intestinal barrier integrity. This evidence is primarily from animal models.
Evidence Strength: Preliminary; predominantly animal and in vitro data. The traditional use as a carminative has historical regulatory recognition (ESCOP, Canadian natural health product monograph), but rigorous human clinical trials are absent.
5.8 Oral Health
Thymol is one of a naturally occurring class of compounds known as biocides, and is the main active ingredient in various commercially produced mouthwashes such as Listerine. Its use in oral hygiene products to control dental plaque and gingivitis is well-established at an applied commercial level.
Evidence Strength: Moderate; thymol's incorporation into clinical-grade mouthwashes is well-supported; direct human trials of thyme herb preparations for oral health are fewer in number but supportive.
5.9 COVID-19 and Immune Response
A prospective, open-label, randomized, controlled, single-center pilot study was conducted in adult outpatients with mild COVID-19. Patients were randomly assigned to the thyme-ivy syrup group, which received three 5.4 mL doses of oral thyme-ivy syrup per day for 14 days, or a control group (no medication). The primary objective was to demonstrate a clinically relevant treatment difference in blood parameters involved in the immune response, including IL-6, IL-10, tumor necrosis factor, and specific blood cell types. On day 7, numerically greater decreases in the thyme-ivy syrup group were observed for some mediators, including IL-10 (−17.7 vs. −6.0 pg/mL; effect size 0.53) and IL-6 levels (−4.9 vs. −0.9 pg/mL; effect size 0.87). Significant between-group differences were observed for changes in some parameters at day 4 and day 14.
Evidence Strength: Very preliminary. This was a small pilot study (n = 21) with significant baseline imbalances, acknowledged as exploratory. No conclusions on clinical benefit for COVID-19 should be drawn from this trial alone.
6. Body Systems and Health Areas Associated with Thyme
- Respiratory system: The most evidenced clinical application — acute bronchitis, upper respiratory catarrh, productive cough, whooping cough, and historically, asthma.
- Gastrointestinal system: Traditional use against gastrointestinal disorders, including carminative (anti-flatulence), antispasmodic, and digestive support applications recognized by ESCOP and Commission E.
- Oral and dental health: Antiseptic use in mouthwashes (thymol-containing products) and historically by dentists for oral abscesses.
- Immune and inflammatory system: Modulation of cytokine production and NF-κB pathways studied preclinically.
- Cardiovascular system: Emerging preliminary evidence for blood pressure reduction and lipid modulation.
- Integumentary (skin): Topical antiseptic applications in wound care historically; current evidence at the in vitro level for acne-related pathogens.
7. Dosage Forms and Dosages Reported in Studies
The following dosages are cited as reported in clinical studies and official regulatory documents:
- In the Gruenwald 2005 trial, the thyme-primrose combination was administered as 30 drops (1 ml) taken orally five times daily over 7–9 days.
- In the Kemmerich 2007 trial, the thyme-primrose dry extract combination was given as 1 tablet three times daily for 11 days.
- In an observational study, patients with bronchial catarrh or bronchitis were treated daily with 15–30 ml of thyme syrup, containing 97.6 mg of thyme liquid extract (DAB) per ml, for a period of 7–14 days (mean 7.9 days).
- In the BroVID COVID-19 pilot study, the thyme-ivy syrup group received three 5.4 mL doses of oral thyme-ivy syrup per day for 14 days.
- In the Nauert & Bentley 2008 study of infants (6–12 months) with acute bronchitis, the study medication was given at a dosage of 1 ml, 6 times daily, over a period of 7 days.
- The European Medicines Agency recommends that the use of thyme be reserved for children older than twelve years; for children aged 12 to 18 years, a dose of 1–2 g (herbal tea/infusion) is referenced.
- No restriction on the duration of use has been reported for thyme herb preparations in traditional indications. The duration of use in clinical studies and observational studies was up to 14 days.
8. Safety Considerations and Interactions
General Safety Profile
No safety concerns have been identified in the broader literature reviewed, and extracts are generally recognized as safe and are GRAS-listed by the FDA. There are no known restrictions on duration of use or contraindications for oral administration. No drug interactions have been reported in the ESCOP monograph context. Thyme-ivy syrup was well tolerated in clinical study conditions, and there were no safety signals of concern.
Essential Oil — Special Caution
Thyme is generally considered a safe herb, and can be used safely with children. The oil, however, should be avoided in high doses both internally and externally as it can be toxic for both adults and children. The essential oil of thyme contains high concentrations of thymol and carvacrol, active ingredients that can be toxic (especially in children), cause allergic reactions, and in high doses can be neurotoxic.
Allergy and Cross-Reactivity
People who are allergic to oregano or other Lamiaceae species might also be allergic to thyme. Thyme is contraindicated for patients with known sensitivity to the Lamiaceae family.
Pregnancy and Lactation
Thyme is commonly consumed in foods during pregnancy. There is not enough reliable information to know if thyme is safe to use in larger medicinal amounts while pregnant or breastfeeding. Staying with food amounts is recommended. The active substances in thyme may pass into breast milk. Using thyme in medicinal quantities while breastfeeding should be avoided.
Bleeding and Coagulation
Thyme might slow blood clotting. Taking thyme might increase the risk of bleeding, especially if used in large amounts. Theoretically, thyme could have additive effects with anticoagulant or antiplatelet medications and possibly increase the risk of bleeding.
Hormone-Sensitive Conditions
Thyme might act like estrogen in the body, a consideration for hormone-sensitive conditions such as breast cancer, uterine cancer, ovarian cancer, endometriosis, or uterine fibroids. Thyme might attach to the same sites in the body as estrogen. By taking up these sites, thyme might reduce the number of sites available for estrogen, potentially decreasing the effects of exogenous estrogen medications.
Drug Interactions
The primary documented theoretical interactions are:
- Anticoagulants/antiplatelets: Thyme could have additive effects with anticoagulant or antiplatelet medications and possibly increase the risk of bleeding.
- Estrogen medications: Taking thyme along with estrogen pills might decrease the effects of estrogen pills.
It should be noted that these interactions are largely theoretical and based on pharmacological reasoning rather than established clinical trial data. The extensive documentation on thyme supports its safe use, with no known contraindications, adverse effects, or interactions with other medications noted in the Commission E monograph. An ESCOP monograph on thyme herb documents the safe oral utilization, confirming the absence of interactions, undesirable effects, overdosing, and contraindications.
Adverse Events in Clinical Trials
In clinical trials, the incidence of adverse events was low and comparable between thyme-containing treatment groups and placebo groups. All adverse events were non-serious. No adverse and/or undesirable effects have been reported except for one potential report of acute kidney injury in a female over 75 years old in 2011, which is available on the VigiAccess-WHO website, and no cases of overdose have been reported.
References
Go back